LLY vs NTRB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NTRB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company is experiencing a catastrophic collapse in top-line growth, with revenue declining by 46.4% YoY, coupled with an unsustainable operating margin of -1121.30%. Despite a high current ratio suggesting short-term liquidity, the valuation is unjustifiable with a Price/Sales ratio of 21.80 for a shrinking, non-profitable entity. The stark contrast between the objective data and the single analyst's 'Strong Buy' recommendation suggests a high-risk speculative environment rather than a value-driven investment.
Compare Another Pair
Related Comparisons
LLY vs NTRB: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Nutriband Inc. (NTRB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.